CA2491802C - Novel compounds, pharmaceutical compositions containing same, and methods of use for same - Google Patents

Novel compounds, pharmaceutical compositions containing same, and methods of use for same Download PDF

Info

Publication number
CA2491802C
CA2491802C CA2491802A CA2491802A CA2491802C CA 2491802 C CA2491802 C CA 2491802C CA 2491802 A CA2491802 A CA 2491802A CA 2491802 A CA2491802 A CA 2491802A CA 2491802 C CA2491802 C CA 2491802C
Authority
CA
Canada
Prior art keywords
compound
subject
animal
human
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA2491802A
Other languages
English (en)
French (fr)
Other versions
CA2491802A1 (en
Inventor
Francis P. Kuhajda
Susan M. Medghalchi
Jill M. Mcfadden
Jagan Thupari
Craig A. Townsend
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Johns Hopkins University
FASgen Inc
Original Assignee
Johns Hopkins University
FASgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Johns Hopkins University, FASgen Inc filed Critical Johns Hopkins University
Priority to CA2767092A priority Critical patent/CA2767092C/en
Publication of CA2491802A1 publication Critical patent/CA2491802A1/en
Application granted granted Critical
Publication of CA2491802C publication Critical patent/CA2491802C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/30—Hetero atoms other than halogen
    • C07D333/32—Oxygen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Obesity (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA2491802A 2002-07-09 2003-07-09 Novel compounds, pharmaceutical compositions containing same, and methods of use for same Expired - Fee Related CA2491802C (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA2767092A CA2767092C (en) 2002-07-09 2003-07-09 Novel compounds, pharmaceutical compositions containing same and methods of use for same

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US39458502P 2002-07-09 2002-07-09
US60/394,585 2002-07-09
PCT/US2003/021700 WO2004005277A1 (en) 2002-07-09 2003-07-09 Novel compunds, pharmaceutical compositions containing same, and methods of use for same

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CA2767092A Division CA2767092C (en) 2002-07-09 2003-07-09 Novel compounds, pharmaceutical compositions containing same and methods of use for same

Publications (2)

Publication Number Publication Date
CA2491802A1 CA2491802A1 (en) 2004-01-15
CA2491802C true CA2491802C (en) 2012-04-10

Family

ID=30115739

Family Applications (2)

Application Number Title Priority Date Filing Date
CA2491802A Expired - Fee Related CA2491802C (en) 2002-07-09 2003-07-09 Novel compounds, pharmaceutical compositions containing same, and methods of use for same
CA2767092A Expired - Fee Related CA2767092C (en) 2002-07-09 2003-07-09 Novel compounds, pharmaceutical compositions containing same and methods of use for same

Family Applications After (1)

Application Number Title Priority Date Filing Date
CA2767092A Expired - Fee Related CA2767092C (en) 2002-07-09 2003-07-09 Novel compounds, pharmaceutical compositions containing same and methods of use for same

Country Status (13)

Country Link
US (2) US7649012B2 (enExample)
EP (3) EP1539730A4 (enExample)
JP (3) JP2005533835A (enExample)
KR (1) KR101087559B1 (enExample)
CN (2) CN101602756B (enExample)
AU (1) AU2003265267B2 (enExample)
BR (1) BRPI0312649A2 (enExample)
CA (2) CA2491802C (enExample)
EA (1) EA013371B1 (enExample)
IL (2) IL166108A0 (enExample)
MX (1) MXPA05000365A (enExample)
SG (1) SG169236A1 (enExample)
WO (1) WO2004005277A1 (enExample)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2474884A1 (en) 2002-02-08 2003-08-14 John Hopkins University School Of Medicine Stimulation of cpt-1 as a means to reduce weight
AU2003265267B2 (en) * 2002-07-09 2010-03-11 Fasgen, Llc Novel compounds, pharmaceutical compositions containing same, and methods of use for same
CN101721412A (zh) * 2002-07-09 2010-06-09 法斯根有限责任公司 治疗人和动物中微生物感染的方法
MXPA06013687A (es) * 2004-05-26 2007-10-18 Fasgen Llc Compuestos novedosos, composiciones farmaceuticas que los contienen y metodos para utilizar los mismos.
AU2007283113A1 (en) 2006-08-08 2008-02-14 Sanofi-Aventis Arylaminoaryl-alkyl-substituted imidazolidine-2,4-diones, processes for preparing them, medicaments comprising these compounds, and their use
CA2668840A1 (en) * 2006-11-08 2008-05-15 Fasgen Llc Novel compounds, pharmaceutical compositions containing same, and methods of use for same
WO2008059214A1 (en) * 2006-11-13 2008-05-22 Astrazeneca Ab Bisamlde derivatives and use thereof as fatty acid synthase inhibitors
EP2285215A4 (en) * 2008-06-02 2012-04-04 Fasgen Inc NOVEL COMPOUNDS, PHARMACEUTICAL COMPOSITIONS THEREFOR AND METHOD OF USE THEREOF
US8470841B2 (en) 2008-07-09 2013-06-25 Sanofi Heterocyclic compounds, processes for their preparation, medicaments comprising these compounds, and the use thereof
WO2010068601A1 (en) 2008-12-08 2010-06-17 Sanofi-Aventis A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof
WO2010118324A2 (en) 2009-04-09 2010-10-14 Nuclea Biotechnologies, LLC Antibodies against fatty acid synthase
US9149445B2 (en) 2009-07-27 2015-10-06 The Trustees Of Princeton University Inhibition of glycerol-3-phosphate acyltransferase (GPAT) and associated enzymes for treatment of viral infections
JP2013503135A (ja) 2009-08-26 2013-01-31 サノフイ 新規な結晶性複素芳香族フルオログリコシド水和物、その化合物を含んでなる医薬及びその使用
WO2011140296A1 (en) 2010-05-05 2011-11-10 Infinity Pharmaceuticals Triazoles as inhibitors of fatty acid synthase
CA2798330A1 (en) 2010-05-05 2011-11-10 Infinity Pharmaceuticals, Inc. Tetrazolones as inhibitors of fatty acid synthase
EP2683703B1 (de) 2011-03-08 2015-05-27 Sanofi Neue substituierte phenyl-oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
WO2012120058A1 (de) 2011-03-08 2012-09-13 Sanofi Mit benzyl- oder heteromethylengruppen substituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012120054A1 (de) 2011-03-08 2012-09-13 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
EP2683699B1 (de) 2011-03-08 2015-06-24 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012120056A1 (de) 2011-03-08 2012-09-13 Sanofi Tetrasubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
US8809324B2 (en) 2011-03-08 2014-08-19 Sanofi Substituted phenyl-oxathiazine derivatives, method for producing them, drugs containing said compounds and the use thereof
EP2683698B1 (de) 2011-03-08 2017-10-04 Sanofi Mit adamantan- oder noradamantan substituierte benzyl-oxathiazinderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
EP2683704B1 (de) 2011-03-08 2014-12-17 Sanofi Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
EP2766349B1 (de) 2011-03-08 2016-06-01 Sanofi Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
WO2012135027A2 (en) * 2011-03-25 2012-10-04 The Research Foundation Of State University Of New York Thiolactone antibiotics
EP2567959B1 (en) 2011-09-12 2014-04-16 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
JP6228198B2 (ja) * 2012-06-25 2017-11-08 トーマス・ジェファーソン・ユニバーシティＴｈｏｍａｓ Ｊｅｆｆｅｒｓｏｎ Ｕｎｉｖｅｒｓｉｔｙ 異常な脂質生合成シグナル伝達を有するがんを処置するための組成物および方法
CA2884355C (en) * 2012-09-07 2022-05-17 Janssen Pharmaceutica Nv Imidazolin-5-one derivative useful as fasn inhobitors for the treatment of cancer
CN112521369A (zh) 2013-03-13 2021-03-19 福马治疗股份有限公司 用于抑制fasn的化合物及组合物
US11202795B2 (en) 2014-11-20 2021-12-21 Vib Vzw Means and methods for treatment of early-onset Parkinson's disease
WO2020092395A1 (en) 2018-10-29 2020-05-07 Forma Therapeutics, Inc. SOLID FORMS OF (4-(2-FLUORO-4-(1-METHYL-1 H-BENZO[d]IMIDAZOL-5-YL)BENZOYL) PIPERAZIN-1-YL)(1-HYDROXYCYCLOPROPYL)METHANONE
CN114480521B (zh) * 2020-11-13 2024-07-26 中国科学院青岛生物能源与过程研究所 一种三氮菌素c的制备方法

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3496187A (en) * 1967-03-20 1970-02-17 American Home Prod N-(heterocyclyl)aconamides
US3472878A (en) * 1969-01-27 1969-10-14 American Home Prod N-(hydroxyaryl)aconamides
JPS5859920A (ja) * 1981-10-05 1983-04-09 Chugai Pharmaceut Co Ltd 生体防禦能賦活剤
US4565699A (en) * 1983-07-18 1986-01-21 The Upjohn Company Composition of matter and process
US4720503A (en) * 1985-08-02 1988-01-19 Merck & Co., Inc. N-substituted fused-heterocyclic carboxamide derivatives as dual cyclooxygenase and lipoxygenase inhibitors
CH667655A5 (de) * 1986-09-24 1988-10-31 Lonza Ag Verfahren zur herstellung von 4-alkoxy-2(5h)-thiophenonen.
US4753871A (en) * 1986-12-12 1988-06-28 Eastman Kodak Company Cyan dye-forming couplers and photographic materials containing same
WO1988004652A1 (fr) * 1986-12-17 1988-06-30 Nippon Soda Co., Ltd. Composes heterocycliques possedant un squelette triketo
US5759837A (en) 1989-01-17 1998-06-02 John Hopkins University Chemotherapy for cancer by inhibiting the fatty acid biosynthetic pathway
US5759791A (en) * 1989-01-17 1998-06-02 The Johns Hopkins University Cancer related antigen
US5665874A (en) * 1989-01-17 1997-09-09 John Hopkins University Cancer related antigen
US5679801A (en) * 1991-04-12 1997-10-21 American Home Products Corporation Tetronic and thiotetronic acid derivatives as phospholipase A2 inhibitors
US5614551A (en) 1994-01-24 1997-03-25 The Johns Hopkins University Inhibitors of fatty acid synthesis as antimicrobial agents
CA2220440A1 (en) * 1995-05-09 1996-11-14 Bayer Aktiengesellschaft Alkyl dihalogenated phenyl-substituted ketoenols useful as pesticides and herbicides
US5981575A (en) 1996-11-15 1999-11-09 Johns Hopkins University, The Inhibition of fatty acid synthase as a means to reduce adipocyte mass
JPH10212284A (ja) * 1996-11-27 1998-08-11 Sagami Chem Res Center テトロン酸−３−カルボン酸誘導体、その製造方法、製造中間体、抗がん剤、及び蛋白脱リン酸化酵素阻害剤
US6391912B1 (en) * 1996-12-12 2002-05-21 Bayer Aktiengesellschaft Substituted phenylketoenols
CO4970714A1 (es) * 1997-09-05 2000-11-07 Boehringer Mannheim Gmbh Derivados ureido y tioureido de 4-amino-2(5h)-furanonas y 4-amino-2(5h) tiofenonas como agentes antitumorales
HN2000000051A (es) * 1999-05-19 2001-02-02 Pfizer Prod Inc Derivados heterociclicos utiles como agentes anticancerosos
IT1315267B1 (it) * 1999-12-23 2003-02-03 Novuspharma Spa Derivati di 2-(1h-indol-3-il)-2-oxo-acetammidi ad attivita'antitumorale
GB0000131D0 (en) * 2000-01-06 2000-02-23 Univ Cardiff Thiolactomycin analogues,compositions containing the same and uses thereof
US6376682B1 (en) * 2000-02-01 2002-04-23 Takama System, Ltd. Compound with α-glucosidase inhibiting action and method for producing the same
EP1383493A4 (en) * 2001-05-02 2005-09-21 Univ New York INHIBITION OF PIGMENTATION BY INHIBITION OF FATTY ACID SYNTHASE
CA2474884A1 (en) * 2002-02-08 2003-08-14 John Hopkins University School Of Medicine Stimulation of cpt-1 as a means to reduce weight
AU2003265267B2 (en) * 2002-07-09 2010-03-11 Fasgen, Llc Novel compounds, pharmaceutical compositions containing same, and methods of use for same
CN101721412A (zh) * 2002-07-09 2010-06-09 法斯根有限责任公司 治疗人和动物中微生物感染的方法
US9690894B1 (en) 2015-11-02 2017-06-27 Altera Corporation Safety features for high level design

Also Published As

Publication number Publication date
US20100120901A1 (en) 2010-05-13
EP1539730A4 (en) 2007-03-28
CN101602756A (zh) 2009-12-16
CA2767092C (en) 2013-10-15
HK1083835A1 (zh) 2006-07-14
KR101087559B1 (ko) 2011-11-29
EP2386550A1 (en) 2011-11-16
AU2003265267B2 (en) 2010-03-11
JP2013189464A (ja) 2013-09-26
JP2011037881A (ja) 2011-02-24
JP2005533835A (ja) 2005-11-10
EP2386551A1 (en) 2011-11-16
CN100513404C (zh) 2009-07-15
IL166108A0 (en) 2006-01-15
US7649012B2 (en) 2010-01-19
SG169236A1 (en) 2011-03-30
MXPA05000365A (es) 2005-09-20
WO2004005277A1 (en) 2004-01-15
EA200500178A1 (ru) 2006-02-24
CA2767092A1 (en) 2004-01-15
BRPI0312649A2 (pt) 2017-05-16
US20060247302A1 (en) 2006-11-02
EA013371B1 (ru) 2010-04-30
IL190218A0 (en) 2008-11-03
CN101602756B (zh) 2014-11-12
CA2491802A1 (en) 2004-01-15
KR20060002007A (ko) 2006-01-06
EP1539730A1 (en) 2005-06-15
AU2003265267A1 (en) 2004-01-23
CN1675192A (zh) 2005-09-28

Similar Documents

Publication Publication Date Title
CA2491802C (en) Novel compounds, pharmaceutical compositions containing same, and methods of use for same
AU2003248810B2 (en) Novel compounds, pharmaceutical compositions containing same, and methods of use for same
US20110288052A1 (en) Novel compounds, pharmaceutical compositions containing same, and methods of use for same
US20090005435A1 (en) Novel Compounds, Pharmaceutical Compositions Containing Same, and Methods of Use for Same
US20100168176A1 (en) Novel compounds, pharmaceutical compositions containing same, and methods of use for same
US20100029752A1 (en) Novel compounds, pharmaceutical compositions containing same, and methods of use for same
US20100029761A1 (en) Novel compounds, pharmaceutical compositions containing same, and methods of use for same

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20160711